KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
75 hedge funds and large institutions have $328M invested in KalVista Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 17 closing their positions.
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
11% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 18
10% more funds holding
Funds holding: 68 → 75 (+7)
5.1% more ownership
Funds ownership: 80.61% → 85.72% (+5.1%)
18% less capital invested
Capital invested by funds: $398M → $328M (-$70.4M)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$14.1M |
| 3 |
DM
Deerfield Management
New York
|
+$13.3M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$10.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$41.2M |
| 2 |
VMI
VHCP Management III
New York
|
-$7.8M |
| 3 |
VMI
VHCP Management II
New York
|
-$4.61M |
| 4 |
Renaissance Technologies
New York
|
-$4.58M |
| 5 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$2.63M |
KALV Hedge Fund Activity: Q2 2019 in Review
75 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2019, worth a combined $328M — down 18% from $398M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new KALV positions and 17 closed out — a net gain of 7 holders — while 20 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $15.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $41.2M sold.
- 75 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2019, up from 68 in Q1 2019.
- Funds reported $328M of KalVista Pharmaceuticals stock for Q2 2019, down 18% quarter-over-quarter.
- 24 funds opened new KalVista Pharmaceuticals positions in Q2 2019 and 17 closed out, a net change of +7 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $15.6M added.
- The largest KalVista Pharmaceuticals seller in Q2 2019 was RA Capital Management, an estimated $41.2M sold.
Based on aggregated 13F filings for Q2 2019.